Biogen to Develop Alkermes' MS Candidate ALKS 8700

Biogen will develop and commercialize Alkermes’ Phase III multiple sclerosis (MS) treatment ALKS 8700, the companies said today, through an up-to-$228 million-plus collaboration designed to neutralize a potential competitive challenge to Biogen’s MS blockbuster Tecfidera ® (dimethyl fumarate).ALKS 8700 is an oral, novel, and proprietary monomethyl fumarate (MMF) prodrug candidate in development for the treatment of relapsing forms of MS. According to Alkermes and Biogen, ALKS 870